Abstract | BACKGROUND: METHODS: Patients were stratified as follows: stratum IA, first recurrence MB with measurable disease; IB, recurrent MB with only cerebral spinal fluid (CSF) positivity or linear leptomeningeal disease (LLD); IC, MB > or =second recurrence; stratum II, recurrent SPNET; stratum III, recurrent ATRT. Patients received oxaliplatin, 130 mg/m(2) intravenously over 2 hours every 3 weeks. The primary objective was to estimate the sustained response rate in stratum 1A. Plasma ultrafiltrate platinum pharmacokinetics were evaluated. RESULTS: A total of 43 patients with a median age of 8.5 years (range, 0.6-18.9 years) were enrolled. In stratum 1A, 2 of 15 had partial responses (PRs, 1 sustained PR). No responses were observed in other strata. The most frequent Grade 3 and 4 toxicities included thrombocytopenia (25.6%), neutropenia (16.3%), leukopenia (12%), increase in serum alanine transaminase (ALT) (7%), vomiting (4.7%), and sensory neuropathy (4.7%). No severe ototoxicity or nephrotoxicity was reported. Plasma ultrafiltrate platinum pharmacokinetic parameters were similar to adults, with a median clearance of 12.2 L/hr (range, 4.4-30 L/hr) and median area under the curve (AUC(0-infinity)) of 9.4 microg/mL/hr (range, 6.2-13.9 microg/mL/hr). CONCLUSIONS:
|
Authors | Maryam Fouladi, Susan M Blaney, Tina Young Poussaint, Burgess B Freeman 3rd, Roger McLendon, Christine Fuller, Adekunle M Adesina, Michael L Hancock, Mary K Danks, Clinton Stewart, James M Boyett, Amar Gajjar |
Journal | Cancer
(Cancer)
Vol. 107
Issue 9
Pg. 2291-7
(Nov 01 2006)
ISSN: 0008-543X [Print] United States |
PMID | 17019740
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | (c) 2006 American Cancer Society. |
Chemical References |
- Antineoplastic Agents
- Organoplatinum Compounds
- Oxaliplatin
|
Topics |
- Adolescent
- Antineoplastic Agents
(administration & dosage, pharmacokinetics, therapeutic use)
- Child
- Child, Preschool
- Female
- Humans
- Infant
- Male
- Medulloblastoma
(drug therapy)
- Neoplasm Recurrence, Local
(drug therapy)
- Neuroectodermal Tumors, Primitive
(drug therapy)
- Organoplatinum Compounds
(administration & dosage, pharmacokinetics, therapeutic use)
- Oxaliplatin
- Rhabdoid Tumor
(drug therapy)
- Supratentorial Neoplasms
(drug therapy)
- Teratoma
(drug therapy)
- Treatment Outcome
|